Potential Glioma treatment, page-2

Here is a video published in 2016 discussing how the Glioblastoma market will expand.


Glioblastoma is the most aggressive form of brain cancer. However, research about this malignant brain tumor has long been one of the lowest funded. Experts predict over 12,000 new cases will occur in 2016.

GlobalData's new projections for Glioblastoma funding indicate a sharp increase in overall funding over the next eight years, causing the market to balloon to more than $3.3 billion in treatment investments by 2024.

Patients with Glioblastoma have very few treatment options due to the location of the tumors. The body's natural blood-brain barrier keeps toxins away from brain tissue, but the impenetrability of the barrier makes it virtually impossible to develop effective drugs. Even after discovering new treatments, researchers must find a reliable way to "trick" the blood-brain barrier into allowing substances through to allow the drug to work.

Right now, Avastin is the standard of care within the market. The drug attacks the tumor indirectly, targeting the area around it. Avastin slows the production of new blood vessels around the tumor, bypassing the blood-brain barrier and starving the tumor.

Bristol-Myers Squibb has a new drug in the development called Opdivo. This drug is expected to take control of the market in 2024 and is already used to treat other cancers, such as small cell lung cancer and kidney cancer. Experts expect approval for use in Glioblastoma treatment in the next 24-36 months. Opdivo is a PD-1 inhibitor, and uses the body's own immune system as the primary weapon against cancer.

Berke Executive Search firm, expects a rise in requests for top-level researchers and project managers with experience in brain cancers due to commitments for future research. The first company to develop an effective and cost efficient treatment for Glioblastoma will reap immense rewards.